Chronic Cancer: A New Category of Survivor

Article

Since 2000, and the hundreds of new approaches to cancer treatment, a new kind of patient has emerged — one who may live years beyond their initial prognosis by moving from treatment to treatment.

Since 2000, and the hundreds of new approaches to cancer treatment, a new kind of patient has emerged — one who may live years beyond their initial prognosis by moving from treatment to treatment.

In 1998, 31-year-old Suzanne Lindley learned she had metastatic colon cancer in her liver, and was told she had six months to live. She and her husband Ronnie reacted by moving to the country from their urban home in Texas to focus on making the time she had left memorable for their two daughters, Katie and Karlie, who were 11 and 8 years old at the time.

Lindley also became adept at using the computer to connect with others in her situation. She was online when one man told her she needed to fight for her life as he had, greatly extending the time the doctors had given him.

It was the first bit of hope she had received; Lindley began chemotherapy for the first time shortly thereafter.

That was 18 years ago, and since then, Lindley has grown into what one doctor called an “advocate extraordinaire.”

The beginning of her journey involved “hitchhiking” from one drug and clinical trial to another. Her goal was to live long enough to see both her daughters graduate.

In 2004, it appeared she would not reach her goal when the clinical trial she was on had no impact on her liver tumors. She felt the end was in sight.

Again she went online, and another friend suggested brachytherapy, a radiation approach which was relatively new and involved sending microspheres, minute glass balls of radiation into the tumor to destroy it from the inside out. She underwent the procedure in 2005 and it destroyed 65 percent of her tumors, allowing her to begin chemotherapy again.

It was also the beginning of the next part of her journey. In 2006, Lindley met Andrew Kennedy, M.D., one of the top researchers in the field of brachytherapy, in Washington, DC, where the two spent the day convincing top lawmakers not to remove brachytherapy from the list of Medicare approved treatments. Kennedy, who she calls her dream maker has become one of Lindley’s greatest supporters. The two have created a new meeting model that brings patients, caregivers and physicians together to provide them information on treatments, as well as direct contact with the physicians and researchers who could extend their lives.

In addition, Lindley created new goals for herself since her daughters were moving on in their own lives. She returned to school, earning a master’s of social work. She also became active with LIVESTRONG and started the nonprofit organization, YES (www.beatlivertunors.org).

Her goal, Lindley says, is to give patients with liver metastases hope and understanding that the diagnosis is not an immediate death sentence.

Read the full story of Lindley’s journey as a chronic cancer patient in Heal®.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content